Compendium of Cancer Genome Aberrations

Changes

HAEM5:Juvenile myelomonocytic leukaemia (view source)

Revision as of 15:34, 30 November 2023

41 bytes removed ,  15:34, 30 November 2023
no edit summary
Line 4: Line 4:  
{{Under Construction}}
 
{{Under Construction}}
   −
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Juvenile Myelomonocytic Leukemia (JMML)]].
+
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Juvenile Myelomonocytic Leukemia (JMML)]].
 
}}</blockquote>
 
}}</blockquote>
 
==Primary Author(s)*==
 
==Primary Author(s)*==
Line 16: Line 16:  
__TOC__
 
__TOC__
   −
==Cancer Category/Type==
+
==Cancer Category / Type==
    
Myeloproliferative neoplasm
 
Myeloproliferative neoplasm
Line 128: Line 128:     
</blockquote>
 
</blockquote>
−
==Individual Region Genomic Gain/Loss/LOH==
+
==Individual Region Genomic Gain / Loss / LOH==
    
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
 
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
Line 213: Line 213:  
<br />
 
<br />
 
</blockquote>
 
</blockquote>
−
==Gene Mutations (SNV/INDEL)==
+
==Gene Mutations (SNV / INDEL)==
    
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
 
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
Line 323: Line 323:  
==Genetic Diagnostic Testing Methods==
 
==Genetic Diagnostic Testing Methods==
   −
Put your text here
      +
*Clinical and hematologic features:
 +
**Peripheral blood monocyte count <u>></u> 1 x 10<sup>9</sup>/L (present in most cases)
 +
**Splenomegaly (present in >95 % cases at presentation)
 +
**Blast percentage in peripheral blood and bone marrow < 20%
 +
**Absence of ''BCR::ABL1''
 +
*Genetic studies (one finding required):
 +
**Somatic mutation in ''PTPN11, KRAS, NRAS,'' or ''RRAS''
 +
**Germline ''NF1'' mutation and loss of heterozygosity of ''NF1'' or clinical diagnosis of neurofibromatosis type 1
 +
**Germline ''CBL'' mutation and loss of heterozygosity of ''CBL''
 +
 +
 +
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Arber|first=Daniel A.|last2=Orazi|first2=Attilio|last3=Hasserjian|first3=Robert P.|last4=Borowitz|first4=Michael J.|last5=Calvo|first5=Katherine R.|last6=Kvasnicka|first6=Hans-Michael|last7=Wang|first7=Sa A.|last8=Bagg|first8=Adam|last9=Barbui|first9=Tiziano|date=2022-09-15|title=International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data|url=https://pubmed.ncbi.nlm.nih.gov/35767897|journal=Blood|volume=140|issue=11|pages=1200–1228|doi=10.1182/blood.2022015850|issn=1528-0020|pmc=9479031|pmid=35767897}}</ref></blockquote>
 
==Familial Forms==
 
==Familial Forms==
   Line 347: Line 358:  
<nowiki>*</nowiki>''Citation of this Page'': “Juvenile myelomonocytic leukaemia”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Juvenile_myelomonocytic_leukaemia</nowiki>.
 
<nowiki>*</nowiki>''Citation of this Page'': “Juvenile myelomonocytic leukaemia”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Juvenile_myelomonocytic_leukaemia</nowiki>.
 
==Other Sections==
 
==Other Sections==
−
Diagnostic Testing Method
  −
  −
  −
  −
*Clinical and hematologic features:
  −
**Peripheral blood monocyte count <u>></u> 1 x 10<sup>9</sup>/L (present in most cases)
  −
**Splenomegaly (present in >95 % cases at presentation)
  −
**Blast percentage in peripheral blood and bone marrow < 20%
  −
**Absence of ''BCR::ABL1''
  −
*Genetic studies (one finding required):
  −
**Somatic mutation in ''PTPN11, KRAS, NRAS,'' or ''RRAS''
  −
**Germline ''NF1'' mutation and loss of heterozygosity of ''NF1'' or clinical diagnosis of neurofibromatosis type 1
  −
**Germline ''CBL'' mutation and loss of heterozygosity of ''CBL''
  −
  −
  −
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Arber|first=Daniel A.|last2=Orazi|first2=Attilio|last3=Hasserjian|first3=Robert P.|last4=Borowitz|first4=Michael J.|last5=Calvo|first5=Katherine R.|last6=Kvasnicka|first6=Hans-Michael|last7=Wang|first7=Sa A.|last8=Bagg|first8=Adam|last9=Barbui|first9=Tiziano|date=2022-09-15|title=International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data|url=https://pubmed.ncbi.nlm.nih.gov/35767897|journal=Blood|volume=140|issue=11|pages=1200–1228|doi=10.1182/blood.2022015850|issn=1528-0020|pmc=9479031|pmid=35767897}}</ref></blockquote>
  −
   
Genetic Susceptibility
 
Genetic Susceptibility
  
Retrieved from "https://content.ccga.io/index.php/Special:MobileDiff/13002"